CONJUGATE VACCINE MARKET ANALYSIS

Conjugate Vaccine Market, by Product Type (Monovalent Conjugate Vaccines and Multivalent Conjugate Vaccine), by Disease Indication (Pneumococcal, Influenza, Meningococcal, and Typhoid), by Pathogen Type ( Bacterial and Viral), by Patient Type ( Pediatric and Adults), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022
Code : CMI2697
Pages :186
Formats :
Excel and PDF
Industry : Biotechnology

Market News

Global Conjugate Vaccine Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors. The private healthcare sector is one such sector, which has been majorly impacted by the pandemic. COVID-19 has also affected the economies in three main ways- by directly affecting the production and demand, by creating disruptions in distribution channels, and through its financial impact on companies and financial markets.

Increasing vaccine approval from the U.S. FDA (Food and Drug Administration) during the pandemic has boosted growth of the global conjugate vaccine market. For instance, in August 2021, Pfizer Inc., a pharmaceutical company and BioNTech SE, a biotechnology company, had announced that the U.S. Food and Drug Administration (FDA) had approved the Biologics License Application (BLA) for COMIRNATY (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. The approval was based on a comprehensive submission package including six-month efficacy and safety data after second dose. Whereas, the vaccine has been available in the U.S. under Emergency Use Authorization (EUA) since December 11, 2020 (as the Pfizer-BioNTech COVID-19 Vaccine).Thus, impact of the Coronavirus (COVID-19) pandemic is expected to boost growth of the global conjugate vaccine market during the pandemic.